Neurocrine Biosciences, Inc. announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the...
Rejuvenate Biomed NV ("Rejuvenate"), a biomedical company developing novel combination drugs for age-related diseases, provides an update on its development pipeline and strategy.
Also Read:...
HepaTx, a biotechnology company focused on innovative off-the-shelf cell therapies to treat late-stage liver disease, announced the Decision to Grant Patent protection by the...
Global biotherapeutics leader CSL Behring today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etranacogene dezaparvovec (EtranaDez)...
Shanghai Henlius Biotech, Inc. announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG has been approved by the National Medical Products Administration (NMPA) for...
